{"prompt": "['NRG Oncology Contact Information', 'Data Managers:', 'Elaine Motyka-Welsh, RN, MSN, CCRP', 'For questions concerning eligibility or', 'NRG Oncology', 'data submission', '1818 Market Street, Suite 1720', 'Philadelphia, PA 19003', '215-574-3216', 'motyka-welshe@nrgoncology.org', 'Roseann Bonanni, CTR, CCRP', 'NRG Oncology', '1818 Market Street, Suite 1720', 'Philadelphia, PA 19003', '215-574-3223', 'bonannir@nrgoncology.org', 'RTQA:', 'Dosimetrist (RTQA questions)', 'For questions concerning RT data', 'Joanne Hunter, BS, RT(T)(R)', 'submission', 'IROC Philadelphia-RT QA Center', 'ACR Clinical Research Center', '1818 Market Street, Suite 1720', 'Philadelphia, PA 19103', '215-574-3222', 'jhunter@acr.org', 'RTQA:', 'Triad-Support@acr.org', 'For questions concerning data', 'submission to TRIAD', 'NRG-GU003', '3', 'Version Date: April 26, 2019']['NRG ONCOLOGY', 'NRG-GU003', 'A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-', 'PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL', 'POST-PROSTATECTOMY RADIATION THERAPY (COPORT)', 'NRG Oncology Contact Information continued', 'Protocol Development:', 'Carol Lam', 'For questions concerning protocol and', 'NRG Oncology', 'informed consent versions & amendments', '1818 Market Street, Suite 1720', 'Philadelphia, PA 19103', '215-717-0848', 'lamc@nrgoncology.org', 'Genitourinary Cancer Committee Chair', 'Current Chair starting March 30, 2018:', 'Felix Feng, MD', '(see Translational Science cover page for', 'contact information)', 'Prior Chair:', 'Howard M. Sandler, MD, MS', 'Department of Radiation Oncology', 'Cedars-Sinai Medical Center', '8700 Beverly Boulevard', 'Los Angeles, CA 90048', '310-423-4234/FAX 310-423-6161', 'Howard.Sandler@cshs.org', 'NRG-GU003', '4', 'Version Date: April 26, 2019']['NRG ONCOLOGY', 'NRG-GU003', 'A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-', 'PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL', 'POST-PROSTATECTOMY RADIATION THERAPY (COPORT)', 'Participating Sites', 'U.S.', 'Canada', 'Approved International Member Sites', 'Document History', 'VersionDate', 'Broadcast Date', 'Amendment 1', 'April 26, 2019', 'N/A', 'Activation', 'June 26, 2017', 'July 28, 2017', 'This protocol was designed and developed by NRG Oncology. It is intended', 'to be used only in conjunction with institution-specific IRB approval for', 'study entry. No other use or reproduction is authorized by NRG Oncology', 'nor does NRG Oncology assume any responsibility for unauthorized use of', 'this protocol.', 'NRG-GU003', '5', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}